Royalty Pharma firms and ups Elan bid
This article was originally published in Scrip
Executive Summary
Royalty Pharma has weighed in with a full and firm offer for Elan, saying it would pay as much as $12 a share in cash for the Irish drug maker. The offer raises the price of Elan to more than $7 billion.